Dr. Zewude[/caption]
Rahel Zewude, MD FRCPC
Infectious Diseases and Medical Microbiology, PGY-5
University of Toronto
MedicalResearch.com: What is the background for this study? Would you describe the syndrome of Auto-brewery syndrome?
Response: Auto-brewery syndrome refers to a syndrome where the gut ferments alcohol from carbohydrates leading to high blood alcohol levels and intoxication without any consumption of alcoholic drinks.
Srivastava Kodavatiganti, MBS[/caption]
Srivastava Kodavatiganti, MBS
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: Prescription and illicit opioid misuse and overdoses have continued to escalate in the U.S. with annual overdoses exceeding 110,000[1]. There was a substantial rise from 2013 to 2022 in the number of opioid-related overdoses due to synthetic opioids [2]. Even nonfatal opioid-involved overdoses increased 4% quarterly between January 2018 and March 2022 as observed by encounters by emergency medical services [3]. Although the eastern U.S. has been particularly impacted by fatal overdoses, annual increases have increased as of last year in the western states including in Nevada (+27.9%), Washington (+36.9%), Oregon (+38.6%), and Alaska (+45.9%). In contrast, other states have seen more modest changes (New Mexico = +1.3%) including decreases (South Dakota = -2.4%, Nebraska = -19.5%) [1]. These findings underscore the importance for understanding patterns in usage of prevention and treatment strategies.
Naloxone is an opioid antagonist which can reverse the effects of an opioid overdose. This crucial lifesaving tool is administered as an injection or as a nasal spray. This study characterized the patterns of naloxone prescriptions in Medicaid patients from 2018 – 2021 and Medicare patients for 2019. State level differences were also quantified as the fold difference in prescribing between the highest and lowest states when correcting for the number of enrollees in each state.
Adopting a healthy lifestyle is essential for enhancing longevity and improving overall well-being, and it involves making conscious choices that benefit both physical and mental health. While physical health often gets the spotlight, mental health is equally crucial. The United States of America is grappling with mental health issues, and San Antonio serves as a bitter reminder. Despite San Antonio investing $26 invested in the Metropolitan Health District's Mental Health initiatives in 2022, much more effort is needed. A new study has revealed that Texas is the state with the worst access to mental healthcare in America. This finding highlights the importance of holistic approaches to health that encompass both mental and physical aspects.
In this guide, we will discuss six key lifestyle modifications that can enhance longevity.
Exercise triggers the release of endorphins, chemicals in the brain that act as natural painkillers and mood lifters. This biochemical shift is crucial for individuals recovering from addiction, as it helps reduce the dependency on substances used to achieve similar feelings. Regular physical activity also helps to establish a routine, a vital component of a stable recovery environment. As exercise becomes a regular part of one’s life, it fosters discipline and a sense of accomplishment, both of which are fundamental in building a sober life.
Dr. Maher[/caption]
Pamela Maher, PhD
Research Professor
Cellular Neurobiology Laboratory
SALK Institute for Biologic Studies
La Jolla California
MedicalResearch.com: What is the background for this study?
Response: Several years ago, we tested several different cannabinoids for protection against the oxytosis/ferroptosis regulated cell death pathway and found CBN (cannabinol) to be one of the most effective. While THC (tetrahydrocannabinol) and CBD (cannabidol) were also quite protective, we wanted to pursue non-psychoactive cannabinoids. Since we are interested in maintaining brain function in the context of aging and disease, we thought that a psychoactive compound could be problematic. In addition, there was already a lot of work on CBD, so we thought we could learn more and contribute more to the field by studying CBN.
Amy Kennalley[/caption]
Amy Kennalley, MBS
First Year Medical Student
Department of Medical Education
Geisinger Commonwealth School of Medicine
MedicalResearch.com: What is the background for this study
Response: The legalization of medical marijuana (MMJ) and the number of qualifying conditions are expanding across the USA, emphasizing the need to understand the implications of MMJ dispensary distribution for equitable access. Pennsylvania (PA) legalized MMJ in 2016, with the first dispensary opening its doors in 2018. The state currently recognizes 24 medical conditions for MMJ use, including six for which there is insufficient or no evidence for their efficacy as a treatment. Prior research suggests that there is a link between proximity to dispensaries and overall MMJ use. However, a gap exists in our understanding of how dispensary locations might be associated with the specific qualifying conditions for which individuals receive their certification.
In response to this knowledge gap, our study delved into the medical marijuana dispensary access in PA and explored associations with both MMJ certifications and the community demographics. Utilizing data from the Pennsylvania Department of Health, we investigated how proximity to MMJ dispensaries related to the proportion of individuals certified for MMJ use within a specific area or Zip Code Tabulation Area. Additionally, we analyzed the proportion of certifications for conditions with varying levels of evidence supporting the efficacy of MMJ.
This pioneering study represents the first of its kind in PA, shedding light on the association between MMJ dispensary locations and certifications. Likewise, it is the first in the US to investigate the link between dispensary locations and specific qualifying conditions. By examining these dynamics, we aim to contribute vital insights to inform policy and practice, ensuring equitable access to MMJ treatment for individuals with diverse medical needs.
Dr. Solgama[/caption]
Jay P. Solgama
Medical Student
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton PA
MedicalResearch.com: What is the background for this study?
Response: The opioid crisis in the United States continues to escalate, with opioid-related deaths increasing by over 800% since 2000. Prescription opioids, particularly oxycodone, have been a contributor to this crisis, with substantial variations in their distribution observed across different states [1,2,3].
Against this backdrop, the study conducted by researchers from the Geisinger Commonwealth School of Medicine aimed to characterize the distribution of oxycodone across US states from 2000 to 2021. By analyzing data from the Drug Enforcement Administration’s comprehensive Automation of Reports and Consolidated Orders System (ARCOS) and the Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research (WONDER) databases, the study sought to identify trends and patterns in oxycodone distribution and their potential implications for opioid-related deaths [4,5].
Dr. Piper[/caption]
Brian J. Piper, PhD
Associate Professor of Neuroscience
Geisinger Commonwealth School of Medicine
Scranton PA 18411
MedicalResearch.com: What is the background for this study?
Response: Many cancer patients use marijuana to treat pain, nausea, or anxiety, often without communicating this with their health care providers. Two observational studies (1, 2) from a single institution in Israel purporting to find a dangerous drug interaction between medical cannabis and immunotherapy have been cited hundreds of times, including by clinical practice guidelines.
The cannabinoid CB2 receptor is found on immune tissues so it is biologically possible that marijuana could make immunotherapies like nivolumab less effective. However, there were anonymous reports on PubPeer (3-5) of many irregularities in the data-analysis. If there were unappreciated differences on other important variables at baseline besides subsequent cannabis use, this could change the interpretation of these influential reports (1, 2). This investigation involved attempting to repeat and verify the data-analysis.
Dr. Madera[/caption]
Joshua D. Madera, MD
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton PA
What is the background for this study?
Response: The US population continues to be drastically impacted by the opioid epidemic, with opioid-related deaths significantly increased compared to European countries. While prescription opioid distribution has gradually declined since its peak in 2011 [1], the rate of opioid prescriptions remains increased compared to 2000.
Furthermore, there is considerable interstate variability in opioid distribution across the US. Identifying patterns in this variability may guide public health efforts to reduce opioid-related harms. Therefore, the primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to explore variations in production quotas and state-level distribution of ten prescription opioids between 2010 and 2019.
Dr. Di Ciano[/caption]
Patricia Di Ciano, PhD
Scientist, Institute for Mental Health Policy Research, Centre for Addiction and Mental Health
Assistant Professor, Department of Pharmacology and Toxicology
University of Toronto
Campbell Family Mental Health Research Institute
Collaborative Program in Neuroscience
MedicalResearch.com: What is the background for this study?
Response: It is now fairly well established that cannabis has a detrimental effect on driving. The most consistently reported effect of cannabis on driving is to increase ‘weaving’ on the road. We know that cannabis use is on the rise in people over 65 years of age. In fact, over the past few years cannabis use is increasing the most in this age group.
Despite this, there are few studies of the effects of cannabis on people over 65; most studies have been conducted on younger adults. We know that there are important age-related changes in the way the body works that may alter the impact of cannabis on the body. Also, older adults may have more experience with cannabis and this can change the effects of cannabis.
It is essential to recognize the diverse manifestations of addiction that have infiltrated our society....
Dr. Kang[/caption]
Jessie Kang, MD, FRCPC
Assistant professor
Department of Diagnostic Radiology
Faculty of Medicine
Dalhousie University
MedicalResearch.com: What is the background for this study?
Those who have never been to rehab before may wonder what it involves. The term conjures images of uniformed healthcare...
Prof. Durazzo[/caption]
Timothy C. Durazzo, PhD
Clinical Neuropsychologist and Research Scientist
Mental Illness Research and Education Clinical Centers
VA Palo Alto Health Care System
Professor, Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
MedicalResearch.com: What is the background for this study?
-There are a limited number of studies investigating changes in human brain structure, in individuals with an alcohol use disorder, with longer term abstinence after treatment.
-Our study was the first to assess for change in cortical thickness over approximately 7 months of abstinence in those seeking treatment of alcohol use disorder.
-Cortical thickness in humans is genetically and phenotypically distinct from other brain structural measures such as cortical volume and surface area.
-Therefore, assessment of changes in cortical thickness with longer-term abstinence provides additional information on how human brain structure recovers with sobriety.
Leana Pande[/caption]
MedicalResearch.com Interview with:
Leana Pande
Touro College of Osteopathic Medicine
MedicalResearch.com: What is the background for this study?
Response: Buprenorphine is not a new drug. It was developed in the 1960s with the intent of providing the benefits of opioids, without the addictive side effects. Unlike many prescription opioids,1 use of this Schedule III drug is increasing.2 It is often characterized as a partial agonist at the mu-opioid receptor (Figure-Right). Buprenorphine is available in many routes of administration and also with (brand name Suboxone) or without naloxone. Buprenorphine is a first-line pharmacotherapy for pregnant women with OUD.3 This review was completed in order for the benefits, and risks, of buprenorphine to be more fully appreciated and inform utilization for both opioid use disorder (OUD) and the treatment of pain.
Prof. Jerlhag Holm[/caption]
Prof. Elisabet Jerlhag Holm
Department of Pharmacology
Institute of Neuroscience and Physiology
The University of Gothenburg
MedicalResearch.com: What is the background for this study?
Response: Alcohol use disorder (AUD) is a conditioned associated with morbidity, mortality and costs for society. There are today 4 approved medications, but given the heterogeneity of the disease the efficacy of these is limited and new medications are needed. Peptides of the gut-brain axis, such as GLP-1, have been implied as novel treatment targets. We therefore investigated the effect of an agonist for GLP-1, semaglutide, on alcohol drinking in rodents.
MedicalResearch.com Interview with:
Lotfi Khemiri
Centre for Psychiatry Research
Stockholm, Sweden
MedicalResearch.com: What is the background for this study?
Response: Our study used large-scale national register data in close to 2 million children, and found that parental abuse of both alcohol and drugs are associated with increased risk of intellectual disability in the offspring. Importantly, the risk increase was observed in both mothers and fathers which to the best of our knowledge is a novel finding, and may be explained by both genetic and environmental factors including toxic effects of substance intake on fetal development.
Luke Cavanah[/caption]
Luke Cavanah, BS
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: It is well-known that schedule II stimulants, which are those that are highly addictive and include amphetamine, methylphenidate, and lisdexamfetamine, have had increasing use and misuse in the US.
Despite understanding the presence of this phenomenon, the reason for it is poorly understood. The purpose of this study was to see if rising rates of schedule II stimulants are related to the legalization of medical marijuana. We were interested in this because schedule II stimulants are primarily used as the treatment for attention-deficit hyperactivity disorder (ADHD), chronic cannabis use has been demonstrated to cause neurocognitive deficits resembling that of ADHD, and the conditions have been shown to affect similar brain regions.
Anyone who has fought to overcome an addiction knows how challenging doing so can be. However, men and women who...
Dr. Kruger[/caption]
Jessica Kruger PhD
Clinical Associate Professor of Community Health and Health Behavior
University at Buffalo School of Public Health and Health Professions
MedicalResearch.com: What is the background for this study?
Response: The 2018 Farm Bill authorizing hemp production led to new cannabinoids in the consumer marketplace. As the market becomes increasingly saturated with suppliers, companies continually diversify available products.
The rapid emergence of novel cannabinoids outpaces systematic research necessary to inform regulations and harm reduction. Empirical evidence is needed to guide policies, practices, and education of consumers. Product manufacturers, social media participants, and cannabis oriented on-line news sources have claimed that THC-O-acetate is a "psychedelic" cannabinoid, producing experiences similar to those associated with LSD, psilocybin, mescaline, and DMT.
Dr. Potnuru[/caption]
Paul Potnuru, MD
Assistant Professor
Anesthesiology, Critical Care and Pain Medicine
The John P. and Kathrine G. McGovern Medical School
The University of Texas Health Science Center at Houston
UTHealth
MedicalResearch.com: What is the background for this study?
Response: The use of cannabis is on the rise in the United States, as it becomes increasingly legally accepted and is viewed as harmless. Furthermore, the potency of cannabis is steadily increasing over time.
There is some evidence from previous studies that compared to non-users, cannabis users require more anesthetics, have higher pain after surgery that requires more opioids, and have an increased risk of postoperative nausea and vomiting.
Given this context of increased usage and potential risks during surgery, we conducted a study to examine the impact of cannabis use on patients undergoing surgery.
Edward Liu[/caption]
Edward Liu, BA
Second year medical student
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA
MedicalResearch.com: What is the background for this study?
Response: The use pattern of two FDA approved cannabinoids, dronabinol (Marinol) and cannabidiol (Epidiolex) has not been previously studied. Dronabinol has been approved in the United States since 1985 for chemotherapy induced nausea as well as vomiting and HIV-induced anorexia,1,2 whereas cannabidiol has been approved since 2018 to treat childhood epileptic disorders, Lennox-Gastaut and Dravet syndrome.3 This longitudinal study examined Medicaid claims between 2016-2020 for these two prescription cannabinoids to better comprehend the state-level pharmacoepidemiologic trends and distribution of these drugs in US Medicaid amidst the increasing use of non-pharmaceutical formulations of cannabis.